Phenotyping and Genotyping of Coagulation Factor V Leiden

Summary

The currently used activated Protein C resistance test demonstrated to be of limited diagnostic value for the detection of the mutant Factor V Leiden. Moreover, this assay is not useful for patients under anticoagulant therapy. A modification of the APC resistance test, applying Factor V deficient plasma is described which demonstrates a specificity and sensitivity of 1.0. The superiority of the modified APC resistance test over the existing APC resistance test was verified by genotyping.

For that purpose, the Amplification Refractory Mutation System (ARMS) was applied to the detection of the G to A mutation at position 1691 in the gene encoding coagulation Factor V. The mutation at that position could be easily detected by using each of two allele-specific oligonucleotide primers concomitantly with one common primer in two separate polymerase chain reactions, thereby amplifying a fragment of 186 base-pairs of the Factor V gene.

• References

• 1 Zöller B, Dahlbäck B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1994; 343: 1536-1568
• 2 Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67
• 3 Voorberg J, Roelse J, Koopman R, Biiller H, Berends F, ten Cate JW, Mer-tens K, van Mourik JA. Association of idiopathic venous thromboembolism with single point-mutation at Arg⁵⁰⁶of factor V. Lancet 1994; 343: 1535-1536
• 4 Greengard JS, Eichinger S, Griffin JH, Bauer KA. Variability of thrombosis among homozygous siblings with resistance to activated Protein C due to an Arg → Gin mutation in the gene for factor V. N Engl J Med 1994; 331: 1559-1562
• 5 Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognised mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-1008
• 6 Dahlbäck B, Hildebrand B. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci USA 1994; 91: 1396-1400
• 7 Sun X, Evatt B, Griffing JH. Blood coagulation factor Va abnormally associated with resistance to activated Protein C in venous thrombophilia. Blood 1994; 83: 3120-3125
• 8 de Ronde H, Bertina RM. Laboratory diagnosis of APC-resistance: a critical evaluation of the test and the development of diagnostic criteria. Thromb Haemost 1994; 72: 880-886
• 9 Trossaërt M, Conard J, Horrellou MH, Samama MM, Ireland H, Bayston TA, Lane DA. Modified APC resistance assay for patients on oral anticoagulants. Lancet 1994; 344: 1709
• 10 Kawasaki ES. Sample preparation from blood, cells, and other fluids. In: PCR Protocols, A guide to methods and Applications Innis MA, Gelfand DH, Sninsky JJ, White TJ. eds San Diego: Academic Press Inc; 1990: 146
• 11 Cripe LD, Moore KD, Kane WH. Structure of the gene for human coagulation factor V. Biochemistry 1992; 31: 3777-3785
• 12 Jenny RJ, Pittman DD, Toole JJ, Kriz RW, Aldape RA, Hewick RM, Kaufman RJ, Mann KG. Complete cDNA and derived amino acid sequence of human factor V. Proc Natl Acad Sci USA 1987; 84: 4846-4850
• 13 Tazelaar JP, Friedman KJ, Kline RS, Guthrie ML, Farber RA. Detection of alpha,-antitrypsin Z and S mutations by polymerase chain reaction-mediated site direction mutagenesis. Clin Chem 1992; 38: 1486-1488
• 14 Newton CR, Graham A, Heptinstall LE, Powell SJ, Summers C, Kalsheker N, Smith JC, Markham AF. Analysis of any point mutation in DNA.. The amplification refractory mutation system (ARMS). Nucleic Acids Res 1989; 17: 2503-2516